Lung cancer Drug's journey through the body tracked in tiny trial
NCT ID NCT07620951
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study will give 8 healthy Chinese men a single dose of the experimental lung cancer drug zorifertinib, which has been tagged with a tiny amount of radioactivity. By collecting blood, urine, and stool samples over two weeks, researchers will track exactly how the drug is broken down and eliminated. The goal is not to test if it works against cancer, but to understand its metabolism and excretion to guide future dosing studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zorifertinib (radioactive-labelled)
What this could lead to
If successful, this study will show how zorifertinib is broken down and removed from the body, which helps design better dosing for future lung cancer patients.
What could go wrong
This is a very early, small study in just 8 healthy people, not patients. It only measures drug processing, not whether the drug works against cancer. Results may not predict effects in sick patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••